Dexmedetomidine Hydrochloride

CHEMBL2106195 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

236.7 g/mol

LogP

—

Phase

4

The hydrochloride salt form of dexmedetomidine used intravenously for ICU sedation and monitored anesthesia care sedation. It produces cooperative sedation where patients remain arousable, making it valuable for neurological assessments.

आणविक भार

236.7400 g/mol

TPSA

28.70 Å²

चिकित्सीय क्षेत्र

अनिद्रा अस्थमा उच्च रक्तचाप एट्रियल फ़िब्रिलेशन क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर डीप वेन थ्रोम्बोसिस / पल्मोनरी एम्बोलिज़्म दर्द प्रबंधन दीर्घकालिक दर्द नॉन-स्मॉल सेल लंग कैंसर पार्किंसन रोग मोटापा सिज़ोफ्रेनिया स्तन कैंसर हृदय विफलता

क्रिया का तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl

InChI

InChI=1S/C13H16N2.ClH/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13;/h4-8,11H,1-3H3,(H,14,15);1H/t11-;/m0./s1

Molecular Formula

C13H17ClN2

HBD / HBA

2 / 1

घूर्णनीय बंधन

2

भारी परमाणु

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

The hydrochloride salt form of dexmedetomidine used intravenously for ICU sedation and monitored anesthesia care sedation. It produces cooperative sedation where patients remain arousable, making it valuable for neurological assessments.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dexmedetomidine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2106195. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918081. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Dexmedetomidine Hydrochloride PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C13H17ClN2
पर्यायवाची: 9

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.